MARKET

RNXT

RNXT

Renovorx Inc
NASDAQ
0.9900
+0.0391
+4.11%
After Hours: 1.020 +0.03 +3.03% 18:17 02/06 EST
OPEN
0.9600
PREV CLOSE
0.9509
HIGH
1.020
LOW
0.9500
VOLUME
308.53K
TURNOVER
--
52 WEEK HIGH
1.500
52 WEEK LOW
0.7006
MARKET CAP
36.28M
P/E (TTM)
-2.2629
1D
5D
1M
3M
1Y
5Y
1D
RenovoRx Appoints Veteran Executive Mark Voll as CFO
TipRanks · 19h ago
RenovoRx appoints Voll as Chief Financial Officer
TipRanks · 1d ago
RenovoRx Appoints Mark Voll CFO, Effective Feb. 1
Benzinga · 1d ago
*RenovoRx Appoints Mark Voll as Chief Financial Officer >RNXT
Dow Jones · 1d ago
RenovoRx Names Mark Voll Chief Financial Officer
Reuters · 1d ago
RENOVORX APPOINTS EXPERIENCED PUBLIC COMPANY EXECUTIVE MARK VOLL AS CHIEF FINANCIAL OFFICER
Reuters · 1d ago
Press Release: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
Dow Jones · 1d ago
Press Release: RenovoRx Appoints Experienced -2-
Dow Jones · 1d ago
More
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Webull offers RenovoRx Inc stock information, including NASDAQ: RNXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNXT stock methods without spending real money on the virtual paper trading platform.